NR 283 Week 6 Assignment; RUA; Pathophysiological Processes; Systemic Lupus Erythematosus

Systemic Lupus Erythematosus Nour Abuomar Chamberlain University College of Nursing NR283: PathophysiologyProfessor Welsch 10/12/2025 Systemic Lupus Erythematosus Systemic lupus erythematosus, also known asl SLE or lupus, is a complex disorder that affects multiple systems of the human body (Murphy, 2022). The exact cause of the disease is unknown. It is believed that impaired immune regulation, influences from the environment, and viral susceptibility may trigger it. Mortality rates remain high due to cardiovascular disease, infections, and lupus nephritis. A thorough clinical assessment should include a comprehensive history, detailed physical examination, and appropriate laboratory testing. Effective management requires an understanding of SLE complications and related comorbidities. SLE is a worldwide health concern that disproportionately affects certain ethnic and racial groups (Barber et al., 2023). People of Asian, Black, Hispanic, and Indigenous backgrounds are among those who experience higher prevalence, incidence, morbidity, and mortality rates. SLE disproportionately impacts women of reproductive age. This higher prevalence among females may be linked to female sex hormones (Murphy, 2022). However, many of the world’s most populous regions, lack up-to-date epidemiological data (Barber et al., 2023). Etiology and Risk Factors Systemic lupus erythematosus (SLE) multisystem chronic disease with an unclear cause, though its development is influenced by a combination of genetic, immunological, endocrine, and environmental factors (Vaillant et al., 2023). Systemic lupus erythematosus (SLE) occurs approximately ten times more frequently in women than in men, and individuals with Klinefelter syndrome (47, XXY) face a 14 times higher risk, pointing to a possible role of X-linked genes. Female sex and hormonal factors are key contributors to SLE susceptibility. Both estrogen and prolactin promote autoimmune responses by increasing the production of B-cells and influencing the function of lymphocytes. Estrogen enhances the activity of immune cells such as CD8+ and CD4+ T cells, B cells, macrophages, and thymocytes. The use of estrogen-based contraceptives and hormone replacement therapy after menopause has been associated with increased disease flares and a higher incidence of SLE. Elevated prolactin levels are also commonly seen in patients with the disease. Environmental triggers also play a significant role in the development of SLE (Vaillent et al., 2023). Certain drugs can induce lupus-like symptoms. Among these, procainamide and hydralazine pose the greatest risk, although more than 100 medications have been implicated. Sulfa drugs are also known to exacerbate symptoms in individuals with SLE. Exposure to ultraviolet (UV) radiation and sunlight can lead to increased cell death and are well-established triggers. Smoking has also been identified as a risk factor. Other potential environmental contributors include exposure to silica, various viral infections, vitamin D deficiency, and consumption of alfalfa sprouts or foods containing canavanine. Pathophysiological Processes The development of systemic lupus erythematosus (SLE) is highly intricate, and understanding of its mechanisms continues to advance (Vaillent et al., 2023). In SLE, the immune system becomes dysregulated, leading to the production of autoantibodies that target the body’s own tissues. This dysregulation involves a breakdown of immune tolerance, resulting in the activation of autoreactive T and B cells. There is an overproduction of